(TheNewswire)
Toronto, Ontario / TheNewswire / August 1,
2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT) is pleased to present an
update on its progress to provide better tools for cardiac analysis to cardiologists to improve diagnosis and treatment of heart
disease.
Completed and Pending Installations of the VMS+ Whole-Heart Analysis System
The Company has installed the first VMS+ in Edmonton at the University of Alberta Mazankowski
Alberta Heart Institute , where it is being used with oncology patients, who require contrast-enhanced ultrasound
imaging. It is also being employed on women with normal and high-risk pregnancies.
About the Mazankowski Alberta Heart Institute (Mazankowski)
Mazankowski is the advanced cardiac care center for Edmonton, Northern and North-Central Alberta, Northern BC,
Saskatchewan, Manitoba, Yukon and Northwest Territories. Located on the Walter C. Mackenzie Health Sciences Centre Campus in
Edmonton, Mazankowski is physically integrated with the University of Alberta and Stollery Children’s Hospitals, making it one of
the very few heart institutes to accommodate both adult and pediatric patients. The Mazankowski has one of the most
technologically advanced Echo Labs in the world providing leading-edge imaging techniques such as 3D, contrast, myocardial
perfusion, speckle tracking and interventional echo.
A second machine will be installed at MD Anderson Hospital in a few weeks and will be used for routine clinical
assessment of oncology patients to determine cardiac changes during and after treatments.
About MD Anderson Cancer Center
MD Anderson has been one of the top two cancer centers in the USA for decades.
It receives the highest number of research grants from the National Cancer Institute and is the recognized leader in the
diagnosis and treatment of cancer. The hospital sees approximately 1.5 million patients a year and performed 575,000 imaging
exams in 2017.
Pending Sales
The Company has 5 pending sales where the cardiology department has an approved budget to purchase the VMS+ and
the Company is awaiting a purchase order. Each of these new users are recognized leaders in cardiac care and will be using
the VMS+ for routine applications as well as research into expanding the application of the VMS+ to inform the best treatment path
to be taken for each patient.
Ongoing Marketing Efforts
The Company exhibited at the Annual Canadian Society of Echocardiography Weekend
from April 12-14, 2018 in Toronto, and the American Society for Echocardiography annual
conference, June 22-26, 2018 in Nashville, Tennessee, and identified a number of potential customers. The conferences had a combined attendance of 3,000 attendees from almost 50 countries .
The sales team is following up with these contacts and reaching out to 300 clinical centers, which have a profile of patients
where the VMS+ would provide significant benefits to their cardiac service. Capital purchases require a long process for
budget approval, as well as signoff by a number of hospital departments, such as bioengineering and IT, before a purchase order is
generated.
Annual General Meeting
The Company will hold its Annual General Meeting on August 13 th at its corporate
offices in Toronto. More details are included in the circular, which has been mailed to shareholders of record.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based
Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the
first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has
developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac
care.
For further information please contact:
Dr. George Adams, CEO, Telephone: (519) 803-6937
Email: gadams@ventripoint.com
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of
applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing",
"may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking
information or statements. The forward-looking statements and information are based on certain key expectations and assumptions
made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking
statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and
information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking
statements and information address future events and conditions, by their very nature they involve inherent risks and
uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks.
Other factors, which could materially affect such forward-looking information are described in the risk factors in the
Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at
www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included
in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained
in this news release are made as of the date hereof and the Corporation undertakes no obligation to update p ublicly or revise any forward-looking statements or information, whether as a result of new information,
future events or otherwise, unless so required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2018 TheNewswire - All rights reserved.